Management of Pyrexia Associated with the Combined Therapy of BRAF and MEK Inhibitors for Melanoma Patients

Abstract

Combined therapies with BRAF and MEK inhibitors are effective treatments for melanoma. However, these therapies are also associated with pyrexia incidence. In this review article, characteristics of pyrexia, such as incidence rate, timing, and recurrence, were reviewed on the basis of reports of clinical trials of BRAF and MEK inhibitors. This article emphasizes key points of pyrexia management in clinical practice, referring to previously reported guidelines, clinical reports, and other review articles. It is expected that the therapeutic outcome of melanoma will be improved further in clinical practice by maximizing the effects of BRAF and MEK inhibitors while managing adverse drug reactions, including pyrexia, appropriately in individual patients.